• News

    News & Agenda

    Prolira is Exhibitor / Sponsor of the European Delirium Association congress Milan (3-4- Nov 2022)
    • Renewed approach to delirium Santeon nurses
      Renewed approach to delirium Santeon nurses Santeon’s new approach to delirium is an innovation by nurses. Delirium is an acute brain failure that causes severe confusion or withdrawal. The impact…
    • Growth capital investment for Prolira for roll-out of brain state monitoring to hospitals
      Growth capital investment for Prolira for roll-out of brain state monitoring to hospitals Investors Borski fund, ROM Utrecht Region, Holland Capital, Health Innovations and Oost NL together invest€5 million in…
    • „PERFECT FIT“: Orion Pharma signs sales collaboration for DeltaScan® in Germany
      The companies ORION Pharma and Prolira are excited to announce their sales collaboration agreement that has been signed in June 2021. The agreement includes the Germany-wide promotion of DeltaScan®, a revolutionary medical device that objectively monitors the brain state of patients. Within minutes, the patient’s brain is assessed for signs of illness (acute encephalopathy and delirium). Monitoring the brain state of hospitalized patients is as important as monitoring other vital organs like the heart or the lungs. Until now this was difficult, as usual care only has subjective checklists with limited performance.
    • DeltaStudy successfully completed
      UMC Utrecht carried out an investigator initiated large scale validation study for DeltaScan device performance, collecting data from a wide study population of 434 hospitalized patients, spread over 9 Dutch hospitals and 31 departments. The aim of the study was to investigate the diagnostic performance of the DeltaScan, a CE-certified device to detect acute encephalopathy and delirium using a brief electroencephalography (EEG) recording, in patients admitted to Intensive Care (ICU), and elderly patients admitted to wards (non-ICU departments).
    • End of international CLEO study reached
      With the consortium partners (UMC Utrecht, Charité and UZ Leuven and Key Opinion Leaders Prof Slooter, NL; Prof Spies, DE; Prof Milisen, BE), we set up the international CLEO evaluation study with the purpose to evaluate DeltaScan in daily practice. The intervention phase was severely hampered by the COVID-19 pandemic. Despite the pandemic, that put a tremendous strain on all hospital staff, thousands of nurses and doctors measured thousands of patients with DeltaScan.
    • Label extension for DeltaScan with acute encephalopathy
      We are proud to announce that the intended use for DeltaScan® has been expanded to include the indication acute encephalopathy, in addition to the existing indication delirium. Encephalopathy means “disease of the brain” and acute encephalopathy is a sudden disturbance and change of (the condition of) the brain that can only be diagnosed on the basis of EEG.
    • EU MDR certification for Prolira!
      We are proud to announce that Prolira is one of the first medical device companies in the world, to be certified according to the new EU MDR.
    • The Epidemic within the Covid19 Pandemic: Delirium
      Article in New York Times (may 2020): Scores of physicians from around the world report a rise in delirium of up to 70% because of Covid-19, says Dr Inouye (USA). It is occurring in both younger and older patients.
    • Delirium care in St Antonius
      St Antonius hospital is one of the first users of DeltaScan, the objective EEG based device to detect & monitor for delirium. They strive to continuously improve delirium care, as it is a common complication. The longer delirium lasts, the worse the patient outcome.

    DeltaScan® is an EU registered trademark (Certificate Nr 018280613) Version 2.0

    Prolira BV
    Padualaan 8
    3584 CH Utrecht
    The Netherlands


    T.
    E.W.


    +31 (0)85 060 1656
    info@prolira.com
    www.prolira.com